DE3478396D1 - Controlled absorption pharmaceutical formulation - Google Patents

Controlled absorption pharmaceutical formulation

Info

Publication number
DE3478396D1
DE3478396D1 DE8484308982T DE3478396T DE3478396D1 DE 3478396 D1 DE3478396 D1 DE 3478396D1 DE 8484308982 T DE8484308982 T DE 8484308982T DE 3478396 T DE3478396 T DE 3478396T DE 3478396 D1 DE3478396 D1 DE 3478396D1
Authority
DE
Germany
Prior art keywords
methyldopa
total
pharmaceutical formulation
controlled absorption
pellet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE8484308982T
Other languages
English (en)
Inventor
Donald Eugene Panoz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Corp PLC
Original Assignee
Elan Corp PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Corp PLC filed Critical Elan Corp PLC
Application granted granted Critical
Publication of DE3478396D1 publication Critical patent/DE3478396D1/de
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE8484308982T 1983-12-21 1984-12-20 Controlled absorption pharmaceutical formulation Expired DE3478396D1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IE3026/83A IE56459B1 (en) 1983-12-21 1983-12-21 Controlled absorption pharmaceutical formulation

Publications (1)

Publication Number Publication Date
DE3478396D1 true DE3478396D1 (en) 1989-07-06

Family

ID=11037484

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8484308982T Expired DE3478396D1 (en) 1983-12-21 1984-12-20 Controlled absorption pharmaceutical formulation

Country Status (9)

Country Link
US (1) US4716040A (de)
EP (1) EP0156077B1 (de)
JP (1) JPS60156612A (de)
AT (1) ATE43497T1 (de)
BE (1) BE901328A (de)
CH (1) CH662506A5 (de)
DE (1) DE3478396D1 (de)
IE (1) IE56459B1 (de)
PH (1) PH20628A (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
IE58401B1 (en) * 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
GB8616669D0 (en) * 1986-07-09 1986-08-13 Merk Sharpe & Dohme Ltd Pharmaceutical compositions
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
US4789549A (en) * 1987-03-09 1988-12-06 Warner-Lambert Company Sustained release dosage forms
EP0856313A1 (de) * 1987-10-16 1998-08-05 ELAN CORPORATION, Plc Diltiazemformulierungen mit gesteuerter Absorption
SE509029C2 (sv) * 1988-08-16 1998-11-30 Ss Pharmaceutical Co Långtidsverkande diklofenak-natriumpreparat
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5122384A (en) * 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
JPH0674206B2 (ja) * 1989-12-28 1994-09-21 田辺製薬株式会社 放出制御型製剤およびその製法
IE82916B1 (en) * 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
NZ242806A (en) * 1991-05-20 1994-01-26 Marion Laboratories Inc Multi-layered acid-containing coated drug beads.
JP2535141B2 (ja) * 1995-01-17 1996-09-18 中外製薬株式会社 フマル酸含有徐放性製剤
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
US6635274B1 (en) 2000-10-27 2003-10-21 Biochemics, Inc. Solution-based transdermal drug delivery system
US20040029959A1 (en) * 2002-08-08 2004-02-12 John Devane Isosorbide mononitrate compositions and methods of their use
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
WO2007011972A2 (en) * 2005-07-19 2007-01-25 Inverseon, Inc. Improved pharmacokinetic profile of beta-adrenergic inverse agonists for the treatment of pulmonary airway diseases
BRPI0707325A2 (pt) * 2006-01-27 2011-05-03 Eurand Inc formulação de dosagem de liberação multiparticulada e método para preparação da mesma
CN103211779B (zh) * 2006-01-27 2016-03-16 阿代尔制药股份有限公司 包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2116256A1 (en) * 1970-12-02 1972-07-13 Sobio Lab Enteric - coated l-dopa - for treatment of parkinsonism with reduced gastrointestinal side-effects
US3965255A (en) * 1974-05-01 1976-06-22 E. E. Eljim Ecology Ltd. Controlled drug releasing preparations
JPS5414649A (en) * 1977-07-06 1979-02-03 Hitachi Ltd Multi-level output circuit
US4230687A (en) * 1978-05-30 1980-10-28 Griffith Laboratories U.S.A., Inc. Encapsulation of active agents as microdispersions in homogeneous natural polymeric matrices
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
SE7813246L (sv) * 1978-12-22 1980-06-23 Haessle Ab Fast farmaceutisk beredning innehallande kroppar med flera ytskikt
CH647676A5 (fr) * 1978-12-22 1985-02-15 Donald E Panoz Formes galeniques a usage oral, a liberation programmee et leurs procedes de preparation.
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3126703A1 (de) * 1981-07-07 1983-01-27 Dr. Karl Thomae Gmbh, 7950 Biberach Bromhexin-retardform und verfahren zu ihrer herstellung
IT1168014B (it) * 1981-08-05 1987-05-20 Erba Farmitalia Forme farmaceutiche a cessione protratta
IE53703B1 (en) * 1982-12-13 1989-01-18 Elan Corp Plc Drug delivery device
US4555399A (en) * 1983-11-18 1985-11-26 Key Pharmaceuticals, Inc. Aspirin tablet
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
US4600645A (en) * 1985-01-31 1986-07-15 Warner-Lambert Company Process for treating dosage forms

Also Published As

Publication number Publication date
JPS60156612A (ja) 1985-08-16
US4716040A (en) 1987-12-29
IE56459B1 (en) 1991-08-14
PH20628A (en) 1987-03-06
BE901328A (fr) 1985-04-16
ATE43497T1 (de) 1989-06-15
EP0156077B1 (de) 1989-05-31
EP0156077A1 (de) 1985-10-02
IE833026L (en) 1985-06-21
CH662506A5 (fr) 1987-10-15

Similar Documents

Publication Publication Date Title
DE3478396D1 (en) Controlled absorption pharmaceutical formulation
PH22003A (en) Pharmaceutical formulation
EP0122077A3 (en) Sustained absorption pharmaceutical composition
DE3773468D1 (de) Hydromorphon-zusammensetzung mit gesteuerter wirkstofffreisetzung.
AU7407387A (en) Controlled release dihydrocodeine composition
NO162103C (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat
DE2966737D1 (en) Polymeric agent for releasing 5-aminosalicylic acid or its derivatives into the gastrointestinal tract, pharmaceutical formulation comprising said agent,method of its preparation and method of preparing said formulation
EP0338383A3 (en) Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture
AU2377588A (en) Controlled absorption diltiazem formulations
DE3367324D1 (en) Pharmaceutical products in sustained-release form, and their preparation process
JPS5441320A (en) Slow release preparation and its manufacturing
JPS5661311A (en) Thial amide or prolonged pharmaceutical preparation comprising its salt

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee